Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Paul Audhya
HSD42 RECENT TRENDS IN ON-DEMAND TREATMENT PRESCRIPTIONS FOR HEREDITARY ANGIOEDEMA: A US CLAIMS DATABASE ANALYSIS
Cookie Preference Center We use cookies which are necessary to make our site work. We may also use additional cookies to analyse, improve and personalise our content and your digital experience. For more information, see our Cookie Policy and the list of Google Ad-Tech Vendors. You may choose not to allow some types of cookies. However, blocking some types may impact your experience of our site and the services we are able to offer.
SA17 ON-DEMAND TREATMENTS FOR HEREDITARY ANGIOEDEMA AND HEALTHCARE RESOURCE UTILIZATION IN PEDIATRIC (2-11 YEARS) PATIENTS: A US CLAIMS DATABASE ANALYSIS
1University of California, Los Angeles, School of Medicine, Los Angeles, CA, USA 2University of Alberta, Edmonton, AB, Canada 3University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt, Germany 4Azienda Ospedale Università di Padova, Padova, Italy 5Bnai Zion Medical Center, Haifa, Israel 6Institute for Asthma and Allergy, Wheaton, MD, USA 7Hôpital Jeanne de Flandre, Lille, France 8Washington University School of Medicine, St. Louis, MO, USA 9University of California, San Diego, La...
Patients experience rapid relief from hereditary angioedema attacks with sebetralstat
You've successfully added Skin Disorders to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Key takeaways: Guidelines recommend rapid use of on-demand treatment for attacks. Median times to reductions in attack severity included 9.27 hours with 300 mg and more than 12 hours with placebo.
A Comparative Bioavailability of Sebetralstat Following Administration of Orally Disintegrating Tablets and Film-Coated Tablets in Healthy Volunteers
Sebetralstat is an investigational oral plasma kallikrein inhibitor for the on-demand treatment of HAE attacks. This trial compares PK characteristics, safety, and tolerability of sebetralstat administered as orally disintegrating tablets (ODT) and film coated tablets (FCT) in healthy volunteers. ODT may improve ease of treatment administration in pediatric and adult HAE populations.
Rapid Plasma Kallikrein Inhibition Following Oral KVD900 is Associated With Early Symptom Relief in Patients With Hereditary Angioedema
Guidelines recommend availability of on-demand therapy for every patient with hereditary angioedema (HAE). We evaluated pharmacokinetics, pharmacodynamics, and time to symptom improvement of the oral plasma kallikrein (PKa) inhibitor KVD900.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Paul
Contact Paul, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack